The information available on our United States Direct Sarms website is provided for educational purposes only
Even after clinical trials are completed, any future use would depend on regulatory approval, indications, safety findings, contraindications, availability and clinical guidance
Importantly, the prevalence of adverse effects does not appear to differ from that observed in patients with T2DM treated with GLP-1 RAs
A randomized clinical study
Still, the clear pattern seen with Wegovy and the higher risk in men suggest that doctors should monitor patients carefully, especially those receiving the higher doses for obesity
For obesity (Zepbound), use E66.01 (morbid obesity due to excess calories) with a supporting Z68 BMI code